ICONIQ Capital LLC Takes Position in GSK PLC Sponsored ADR $GSK

Key Points

• ICONIQ Capital LLC has acquired a new stake in GSK PLC, purchasing 11,888 shares valued at approximately $461,000 in the first quarter.
• A number of institutional investors have also increased their stakes in GSK, with holdings increasing significantly by firms like HHM Wealth Advisors and Cary Street Partners.
• GSK reported earnings of $1.23 EPS for the last quarter, exceeding estimates, with a revenue of $10.64 billion, reflecting a year-over-year growth.

ICONIQ Capital LLC purchased a new position in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 11,888 shares of the pharmaceutical company's stock, valued at approximately $461,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Dodge & Cox lifted its holdings in shares of GSK by 14.9% in the first quarter. Dodge & Cox now owns 78,651,833 shares of the pharmaceutical company's stock worth $3,046,972,000 after buying an additional 10,210,921 shares in the last quarter. Primecap Management Co. CA increased its position in shares of GSK by 1.8% in the first quarter. Primecap Management Co. CA now owns 25,708,020 shares of the pharmaceutical company's stock worth $995,929,000 after purchasing an additional 446,360 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of GSK by 2.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 7,722,314 shares of the pharmaceutical company's stock worth $299,163,000 after purchasing an additional 155,392 shares during the last quarter. Equity Investment Corp increased its position in shares of GSK by 5.3% in the first quarter. Equity Investment Corp now owns 4,174,189 shares of the pharmaceutical company's stock worth $161,708,000 after purchasing an additional 211,608 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of GSK by 0.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,598,570 shares of the pharmaceutical company's stock worth $87,884,000 after purchasing an additional 18,492 shares during the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently weighed in on GSK. Berenberg Bank restated a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. Wall Street Zen upgraded shares of GSK from a "hold" rating to a "buy" rating in a research report on Sunday, August 3rd. Six investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Reduce" and a consensus target price of $37.38.

GSK Price Performance

GSK traded up $0.24 during midday trading on Friday, hitting $39.68. The stock had a trading volume of 3,590,956 shares, compared to its average volume of 3,181,567. The company has a market cap of $80.82 billion, a P/E ratio of 18.37, a price-to-earnings-growth ratio of 1.71 and a beta of 0.51. The business has a fifty day moving average of $38.40 and a 200 day moving average of $38.22. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.57 and a current ratio of 0.87. GSK PLC Sponsored ADR has a 1 year low of $31.72 and a 1 year high of $44.26.

GSK (NYSE:GSK - Get Free Report) last issued its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.11. The business had revenue of $10.64 billion during the quarter, compared to analyst estimates of $7.92 billion. GSK had a return on equity of 49.22% and a net margin of 10.81%.GSK's revenue for the quarter was up 1.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.43 earnings per share. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. As a group, equities analysts forecast that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Cuts Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 9th. Stockholders of record on Friday, August 15th will be paid a dividend of $0.4206 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date of this dividend is Friday, August 15th. GSK's dividend payout ratio is 77.78%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.